

## CLAIMS

1. Use of a substance which inhibits the production and/or the effect of estrogens, or a composition containing said substance, for the stabilization, the increase and/or the restoration of collagen.
2. Use according to claim 1, characterized in that the substance is selected from the group consisting of aromatase inhibitors and anti-estrogens.
3. Use according to claim 1, characterized in that the substance is an aromatase inhibitor.
4. Use according to claim 1, characterized in that the substance is derived from soya glycine.
5. Use according to claim 4, characterized in that the substance from soya glycine had been treated by oxidation.
6. Use according to any of the preceding claims, characterized in that the substance is contained in the composition in an amount of 0.001 to 5 wt.-%, relative to the total amount of the composition.
7. Use according to any one of the preceding claims, characterized in that the composition comprises both an aromatase inhibitor and an anti-estrogen.
8. Use according to any one of the preceding claims, characterized in that an inhibition of the production and/or the effect of dihydrotestosterone is performed at the same time or in addition.

9. Use according to claim 8, characterized in that an aromatase inhibitor is combined with a 5-alpha-reductase inhibitor.

10. Use according to claim 7, characterized in that a substance is used which has both an inhibitory effect on aromatase and on 5-alpha-reductase.

11. Use according to any one of the preceding claims, characterized in that a local application is performed.

10

12. Use according to any one of the preceding claims, characterized in that it serves for cosmetic purposes.

15

13. Use according to any one of the preceding claims, characterized in that it serves for the stabilization, the increase and/or the restoration of collagen in one or more of the following body regions: skin, ligaments, fasciae, tendons, cartilages, bones, dentine and the vessel walls of arteries, veins and urinary passageways.

20

14. Use according to any one of the preceding claims, characterized in that the substance is contained in a pharmaceutical formulation which is suitable for the topical application, for injection, for inhalation or for transdermal therapy.

25

15. Use of a substance which inhibits the production and/or the effect of estrogens, or a composition containing said substance, for the prophylaxis of myocardial infarction and brain infarction.

30

16. Use of a substance which inhibits the production and/or the effect of estrogens, or a composition containing said substance, for the prophylaxis or therapy of osteoporosis.

17. Use of a substance which inhibits the production and/or the effect of estrogens, or a composition containing said substance, for the prophylaxis or therapy of arteriosclerosis.

5 18. Use of a substance which inhibits the production and/or the effect of estrogens, or a composition containing said substance, for the prophylaxis or therapy of urinary incontinence.

10 19. Use of a substance which inhibits the production and/or the effect of estrogens, or a composition containing said substance, for the prophylaxis or therapy in the case of excessive production of glucocorticoids in the body, or as a therapy accompanying the therapeutic use of glucocorticoids for the decrease of side effects which are associated with glucocorticoids.

15 20. Use of a substance which inhibits the production and/or the effect of estrogens, or a composition containing said substance, for the decrease of hair growth in women.

20 21. Use of a substance which inhibits the production and/or the effect of estrogens, or a composition containing said substance, for the cosmetic treatment of wrinkles and/or strias of the skin as well as atony of the upper skin.

25 22. Use of a substance which inhibits the production and/or the effect of estrogens, or a composition containing said substance, for the amelioration of sun exposure to the skin.

30 23. Use according to any one of claims 15 to 22, characterized in that a substance or a composition as defined in any one of claims 2 to 10 is used.

35 24. Cosmetic composition for topical application, characterized in that the composition comprises one or more substance(s) such

that the production and/or the effect of estrogens and, at the same time, the production and/or the effect of dihydrotestosterone is inhibited.

5 25. Cosmetic composition according to claim 24, characterized in that an aromatase inhibitor is combined with a 5-alpha-reductase inhibitor.

10 26. Cosmetic composition according to claim 24, characterized in that the composition comprises a substance which has both an inhibitory effect on aromatase and on 5-alpha-reductase.